Pharma Focus Asia
Eppendorf Bioprocess Solutions

Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment

Tuesday, November 24, 2020

Novellus, Ltd., a clinical-stage biotechnology company focused on precision oncology, and Tempus, a leader in artificial intelligence and precision medicine, announced their collaboration to accelerate patient enrollment for Novellus’ next generation BRAF inhibitor program.

Novellus’ BRAF program focuses on patient populations for which there are currently no FDA-approved BRAF inhibitors, including BRAF fusions and BRAF-mutated gliomas. Novellus will participate in Tempus’s TIME Trial® Network, and the companies will work together to identify relevant patients to accelerate patient enrollment.

“The collaboration with Tempus will enable us to accelerate the enrollment of patients in our BRAF trial, by precisely identifying potential candidates and opening sites wherever the patients are found” said Michael Vidne, Chief Executive Officer of Novellus.

“The TIME Trial Program has achieved an unparalleled scale thus far, with over 50 provider networks and 2,500 oncologists included in its network,” said Kim Blackwell, Chief Medical Officer of Tempus. “We’re excited to collaborate with Novellus, to further our mission to increase trial participation, and to ultimately bring the right treatment to the right patients at the right time.”

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACPHI Korea 2023Bora Pharmaceutical - A robust approach to analytical testing is essentialSelangor International Expo MEDIC 2023TFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile AppCPHI & PMEC China 20233rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023Pharma Regulatory Conclave 202320th Anniversary Hospitalog Asia 2023
Charles River Laboratories - Endosafe Compendial LAL Cartridge Technology